Published in Biochem J on July 01, 1991
Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A (1996) 2.93
Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest (1995) 2.53
Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A (1991) 2.53
Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest (2000) 2.39
The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest (1992) 2.04
Matrilysin expression and function in airway epithelium. J Clin Invest (1998) 1.94
Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A (1996) 1.92
Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J (1997) 1.85
Physiology and pathophysiology of matrix metalloproteases. Amino Acids (2010) 1.83
Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest (2004) 1.82
Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol (1996) 1.72
Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol (1994) 1.60
The metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue-restricted pattern in the mouse. Mol Biol Cell (1995) 1.60
Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol (2003) 1.58
Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J Clin Invest (1993) 1.56
Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J Clin Invest (1994) 1.52
The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J (1992) 1.49
Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest (1998) 1.44
Bacterial exposure induces and activates matrilysin in mucosal epithelial cells. J Cell Biol (2000) 1.41
Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol (1998) 1.38
Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest (1992) 1.38
Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest (1993) 1.36
Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J (1992) 1.27
Entactin stimulates neutrophil adhesion and chemotaxis through interactions between its Arg-Gly-Asp (RGD) domain and the leukocyte response integrin. J Clin Invest (1992) 1.27
92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest (1994) 1.26
MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis (2000) 1.26
Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut (2004) 1.21
Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell (2004) 1.18
92-kd gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma. Am J Pathol (1993) 1.18
Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer (1996) 1.16
Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum. Biochem J (1995) 1.11
Expression of gelatinase B in trachomatous conjunctivitis. Br J Ophthalmol (2000) 1.11
Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids. Biochem J (1995) 1.10
Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer (2001) 1.09
Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations. Am J Pathol (2001) 1.07
Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol (1997) 1.06
Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J (1996) 1.05
Complete degradation of type X collagen requires the combined action of interstitial collagenase and osteoclast-derived cathepsin-B. J Clin Invest (1995) 1.04
Monocytic cell type-specific transcriptional induction of collagenase. J Clin Invest (1996) 1.02
Immunohistochemical localisation of the matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma. Thorax (1999) 1.02
Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am J Pathol (1994) 1.01
Advances in animal cell recombinant protein production: GS-NS0 expression system. Cytotechnology (2000) 1.00
Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol (2001) 1.00
The gelatin-binding site of human 72 kDa type IV collagenase (gelatinase A). Biochem J (1994) 1.00
Overexpression of the matrix metalloproteinase matrilysin results in premature mammary gland differentiation and male infertility. Mol Biol Cell (1998) 0.99
Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem J (1995) 0.97
Molecular characterization of a low-molecular-mass matrix metalloproteinase secreted by glomerular mesangial cells as PUMP-1. Biochem J (1992) 0.97
Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein. Biochem J (1993) 0.96
Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases. Clin Exp Metastasis (1997) 0.95
Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer (2001) 0.94
Spotlight on differentially expressed genes in urinary bladder cancer. PLoS One (2011) 0.94
Activity-dependent shedding of the NMDA receptor glycine binding site by matrix metalloproteinase 3: a PUTATIVE mechanism of postsynaptic plasticity. PLoS One (2008) 0.94
Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice. Immunology (2004) 0.94
Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. Clin Exp Metastasis (2005) 0.94
Association of matrix metalloproteinase-7 (-181A>G) polymorphism with risk of esophageal squamous cell carcinoma in Kashmir Valley. Saudi J Gastroenterol (2011) 0.91
Cellular distribution of 92-kd type IV collagenase/gelatinase B in human hepatocellular carcinoma. Am J Pathol (1996) 0.90
Discoidin domain receptors regulate the migration of primary human lung fibroblasts through collagen matrices. Fibrogenesis Tissue Repair (2012) 0.90
Loss of Timp3 gene leads to abdominal aortic aneurysm formation in response to angiotensin II. J Biol Chem (2012) 0.89
Matrix metalloproteinase-9 (92-kd gelatinase/type IV collagenase equals gelatinase B) can degrade arterial elastin. Am J Pathol (1994) 0.88
Inhibitors of collagenase but not of gelatinase reduce cartilage explant proteoglycan breakdown despite only low levels of matrix metalloproteinase activity. Clin Mol Pathol (1996) 0.87
Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2006) 0.87
Metalloproteinases and Wound Healing. Adv Wound Care (New Rochelle) (2015) 0.84
Stromelysin 1, neutrophil collagenase, and collagenase 3 do not play major roles in a model of chondrocyte mediated cartilage breakdown. Mol Pathol (1998) 0.83
Dysregulation of renal MMP-3 and MMP-7 in canine X-linked Alport syndrome. Pediatr Nephrol (2005) 0.82
Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture. Biochem J (1996) 0.82
The loss of tuberin promotes cell invasion through the ß-catenin pathway. Am J Respir Cell Mol Biol (2009) 0.82
Collagen turnover is diminished by different clones of skin fibroblasts from early- but not late-stage systemic sclerosis. Rheumatol Int (2003) 0.81
Inostamycin, an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line. Clin Exp Metastasis (2000) 0.81
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs (2006) 0.81
Parallel expression of macrophage metalloelastase (MMP-12) in duodenal and skin lesions of patients with dermatitis herpetiformis. Gut (2001) 0.80
The inhibitor of kappa B kinase-epsilon regulates MMP-3 expression levels and can promote lung metastasis. Oncogenesis (2014) 0.78
Increased matrix metalloproteinase-9 activity in human ovarian cancer cells cultured with conditioned medium from human peritoneal tissue. Clin Exp Metastasis (1997) 0.78
Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir Res (2015) 0.77
Elimination of p19(ARF)-expressing cells enhances pulmonary function in mice. JCI Insight (2016) 0.77
Regulation of MT1-MMP/MMP-2/TIMP-2 axis in human placenta. J Inflamm Res (2015) 0.77
Loss of laminin and of the laminin receptor integrin subunit alpha 6 in situ correlates with cytokine induced down regulation of alpha 6 on fibroblast-like synoviocytes from rheumatoid arthritis. Ann Rheum Dis (1998) 0.76
Sphingomyelinase D from Loxosceles laeta Venom Induces the Expression of MMP7 in Human Keratinocytes: Contribution to Dermonecrosis. PLoS One (2016) 0.76
Inhibition of gelatinase activity in human airway epithelial cells and fibroblasts by dexamethasone and beclomethasone. Br J Pharmacol (1999) 0.75
Toll-like receptor 2 activation and serum amyloid A regulate smooth muscle cell extracellular matrix. PLoS One (2017) 0.75
Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine. Br J Clin Pharmacol (2011) 0.75
Maturation of the head of bacteriophage T4. I. DNA packaging events. J Mol Biol (1973) 33.51
Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. Science (1981) 23.67
The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J (1973) 22.93
A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res (1982) 7.12
Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry (1982) 6.87
Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet (1990) 5.65
H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem (1988) 4.06
A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem (1986) 2.65
Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest (1990) 2.56
The collagenase gene family in humans consists of at least four members. Biochem J (1988) 2.45
Mouse macrophage elastase. Purification and characterization as a metalloproteinase. Biochem J (1981) 2.38
Purification and characterization of a rabbit bone metalloproteinase that degrades proteoglycan and other connective-tissue components. Biochem J (1983) 2.17
Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J (1989) 1.89
The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis (1990) 1.80
Metalloproteinases from rabbit bone culture medium degrade types IV and V collagens, laminin and fibronectin. Biochem J (1981) 1.62
Purification and properties of a small latent matrix metalloproteinase of the rat uterus. J Biol Chem (1988) 1.61
Elastinolytic activity of human cathepsin L. Biochem J (1986) 1.48
Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol (1989) 1.41
Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. Cancer Res (1990) 1.38
Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. Biochemistry (1989) 1.35
The construction of a highly efficient and versatile set of mammalian expression vectors. Nucleic Acids Res (1989) 1.30
An improved assay for proteases and polysaccharidases employing a cartilage proteoglycan substrate entrapped in polyacrylamide particles. Anal Biochem (1980) 1.29
Characterization of the procollagen IV cleavage products produced by a specific tumor collagenase. J Biol Chem (1984) 1.28
Purification of recombinant human prostromelysin. Studies on heat activation to give high-Mr and low-Mr active forms, and a comparison of recombinant with natural stromelysin activities. Biochem J (1991) 1.24
Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen. J Biol Chem (1990) 1.21
Purification of the neutral proteoglycan-degrading metalloproteinase from human articular cartilage tissue and its identification as stromelysin matrix metalloproteinase-3. Biochem J (1989) 1.20
Role and regulation of metalloproteinases in connective tissue turnover. Biochem Soc Trans (1990) 1.17
Inhibition of type I collagen film degradation by tumour cells using a specific antibody to collagenase and the specific tissue inhibitor of metalloproteinases (TIMP). Cell Biol Int Rep (1985) 1.10
Gelatinase (type IV collagenase) immunolocalization in cells and tissues: use of an antiserum to rabbit bone gelatinase that identifies high and low Mr forms. J Cell Sci (1989) 1.10
Effect of cytokines and growth factors on the expression of elastase activity by human synoviocytes, dermal fibroblasts and rabbit articular chondrocytes. Biochem Biophys Res Commun (1988) 0.88
Use of inhibitory (anti-catalytic) antibodies to study extracellular proteolysis. Immunol Invest (1989) 0.87
Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J (1987) 4.56
Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature (1985) 3.97
Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J (1986) 3.31
TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett (1998) 3.04
Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J (1987) 2.54
The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol (1992) 2.19
A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol (1997) 2.13
The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett (2000) 2.03
The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem (1992) 1.85
Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem (1998) 1.65
Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem (2000) 1.56
Elevated plasma stromelysin levels in arthritis. J Rheumatol (1994) 1.54
The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J (1992) 1.49
Antisense oligonucleotide-induced reduction in 5-hydroxytryptamine7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. J Neurochem (1998) 1.43
Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem (1995) 1.41
Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J (1995) 1.41
The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry (1991) 1.41
The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry (1993) 1.36
Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem (1994) 1.34
The construction of a highly efficient and versatile set of mammalian expression vectors. Nucleic Acids Res (1989) 1.30
Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta (1991) 1.28
Purification and characterization of human 72-kDa gelatinase (type IV collagenase). Use of immunolocalisation to demonstrate the non-coordinate regulation of the 72-kDa and 95-kDa gelatinases by human fibroblasts. Biol Chem Hoppe Seyler (1991) 1.24
Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem (1994) 1.23
Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1 )integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci (2000) 1.21
Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci (1999) 1.20
Metalloproteinases and tissue damage. Br J Rheumatol (1991) 1.18
Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family. Biochemistry (1994) 1.18
Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp (1998) 1.18
Selective uncoupling of RGS action by a single point mutation in the G protein alpha-subunit. J Biol Chem (1998) 1.15
The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci (1994) 1.10
RGS7 is palmitoylated and exists as biochemically distinct forms. J Neurochem (2000) 1.05
Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J (1999) 1.05
Molecular cloning and nucleotide sequence of rat lingual lipase cDNA. Nucleic Acids Res (1985) 1.03
Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology (1995) 1.03
Restriction fragment length polymorphism analysis and assignment of the metalloproteinases stromelysin and collagenase to the long arm of chromosome 11. Genomics (1988) 1.02
NMR structure of free RGS4 reveals an induced conformational change upon binding Galpha. Biochemistry (2000) 1.00
Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix (1990) 0.99
Gelatinase A (MMP-2) and cysteine proteinases are essential for the degradation of collagen in soft connective tissue. Matrix Biol (1998) 0.99
Mutation of the active site glutamic acid of human gelatinase A: effects on latency, catalysis, and the binding of tissue inhibitor of metalloproteinases-1. Biochemistry (1994) 0.98
Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain. Eur J Biochem (1993) 0.98
Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem J (1999) 0.97
Distribution of heterotrimeric G-protein beta and gamma subunits in the rat brain. Neuroscience (1998) 0.96
Regional distribution of regulators of G-protein signaling (RGS) 1, 2, 13, 14, 16, and GAIP messenger ribonucleic acids by in situ hybridization in rat brain. Brain Res Mol Brain Res (2001) 0.96
The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEBS Lett (1996) 0.95
Extracellular matrix and matrix metalloproteinases in sciatic nerve. J Neurosci Res (2003) 0.95
Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J (1995) 0.94
Active gelatinase B is identified by histozymography in the cartilage resorption sites of developing long bones. Dev Dyn (1999) 0.93
Metalloproteinase domain structure, cellular invasion and metastasis. Biochem Soc Trans (1994) 0.93
Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis (1997) 0.92
Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis. FEBS Lett (1997) 0.92
Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer (1995) 0.91
Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. Biochemistry (1994) 0.90
Collagen breakdown in soft connective tissue explants is associated with the level of active gelatinase A (MMP-2) but not with collagenase. Matrix Biol (1999) 0.90
Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. J Rheumatol (1999) 0.89
Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodontal Res (1989) 0.89
Matrix metalloproteinase inhibitors block osteoclastic resorption of calvarial bone but not the resorption of long bone. Ann N Y Acad Sci (1999) 0.88
Expression, purification, and functional analysis of the human serine protease HtrA2. Protein Expr Purif (2000) 0.88
RGS7 attenuates signal transduction through the G(alpha q) family of heterotrimeric G proteins in mammalian cells. J Neurochem (1998) 0.88
Reciprocated matrix metalloproteinase activation: a process performed by interstitial collagenase and progelatinase A. Biochemistry (1994) 0.88
Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. Biochemistry (1992) 0.88
Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases. Biochem J (1992) 0.87
Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res (1996) 0.86
Site-directed mutations that alter the inhibitory activity of the tissue inhibitor of metalloproteinases-1: importance of the N-terminal region between cysteine 3 and cysteine 13. Biochemistry (1992) 0.86
Alzheimer's disease: correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome. J Neurochem (1999) 0.85
Immunohistochemical distribution of RGS7 protein and cellular selectivity in colocalizing with Galphaq proteins in the adult rat brain. J Neurochem (1999) 0.85
Pindolol-insensitive [3H]-5-hydroxytryptamine binding in the rat hypothalamus; identity with 5-hydroxytryptamine7 receptors. Br J Pharmacol (1999) 0.84
Inhibition of the metalloproteinase domain of mouse TACE. Ann N Y Acad Sci (1999) 0.84
Cloning and tissue distribution of the human G protein beta 5 cDNA. Biochim Biophys Acta (1998) 0.84
A fibrosarcoma model derived from mouse embryo cells: growth properties and secretion of collagenase and metalloproteinase inhibitor (TIMP) by tumour cell lines. Int J Cancer (1984) 0.83
Chromosomal assignment of the gene encoding the human tissue inhibitor of metalloproteinases to Xp11.1-p11.4. Ann Hum Genet (1987) 0.82
The role of exon 5 in fibroblast collagenase (MMP-1) substrate specificity and inhibitor selectivity. Eur J Biochem (2001) 0.81
The modulation of the rate of inactivation of the mKv1.1 K+ channel by the beta subunit, Kv beta 1 and lack of effect of a Kv beta 1 N-terminal peptide. FEBS Lett (1996) 0.80
Assignment of the TIMP gene to the murine X-chromosome using an inter-species cross. Nucleic Acids Res (1987) 0.80
New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. J Med Chem (1997) 0.79
Mouse cell lines that use heat shock promoters to regulate the expression of tissue plasminogen activator. DNA (1987) 0.78
Recombinant tissue inhibitor of metalloproteinases type 1 suppresses alkali-burn-induced corneal ulceration in rabbits. Invest Ophthalmol Vis Sci (1994) 0.78
Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment. Ann N Y Acad Sci (1994) 0.78
An in vivo model for screening peptidomimetic inhibitors of gelatinase A. J Pharm Sci (1995) 0.77
Enhanced neuronal differentiation of NTera-2 cells expressing neuronally restricted beta2 adrenergic receptor. Brain Res (1998) 0.76
Presenilins--in search of functionality. Biochem Soc Trans (1998) 0.75
Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analyses. Biochem J (1996) 0.75
LEAD POISONING IN BRASS AND BRONZE FOUNDRIES. Can Med Assoc J (1931) 0.75
Interaction between progelatinase A and TIMP-2. Ann N Y Acad Sci (1994) 0.75
Crystallization and preliminary X-ray analysis of nonglycosylated tissue inhibitor of metalloproteinases-1, N30QN78Q TIMP-1. Proteins (1993) 0.75
1H, 15N, 13C, and 13CO assignments and secondary structure determination of RGS4. J Biomol NMR (1999) 0.75
The literary works of Sir William Osler. Osler Libr Newsl (1977) 0.75
The binding of gelatinases A and B to type I collagen yields both high and low affinity sites. Ann N Y Acad Sci (1994) 0.75
Automobile Fatalities in 1929. Can Med Assoc J (1930) 0.75